JP2005515217A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005515217A5 JP2005515217A5 JP2003556430A JP2003556430A JP2005515217A5 JP 2005515217 A5 JP2005515217 A5 JP 2005515217A5 JP 2003556430 A JP2003556430 A JP 2003556430A JP 2003556430 A JP2003556430 A JP 2003556430A JP 2005515217 A5 JP2005515217 A5 JP 2005515217A5
- Authority
- JP
- Japan
- Prior art keywords
- solvent mixture
- decapeptide
- nonapeptide
- precipitation
- alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 24
- 238000001556 precipitation Methods 0.000 claims description 18
- 239000011877 solvent mixture Substances 0.000 claims description 18
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 14
- 239000012156 elution solvent Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 4
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 claims description 4
- 239000002474 gonadorelin antagonist Substances 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 2
- RMOUBSOVHSONPZ-UHFFFAOYSA-N Isopropyl formate Chemical compound CC(C)OC=O RMOUBSOVHSONPZ-UHFFFAOYSA-N 0.000 claims description 2
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 claims description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 2
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 claims description 2
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 claims description 2
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 claims description 2
- 229940017219 methyl propionate Drugs 0.000 claims description 2
- GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 claims description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims description 2
- 239000002798 polar solvent Substances 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- 235000019260 propionic acid Nutrition 0.000 claims description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 2
- -1 t- butyl Chemical group 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 108700012941 GNRH1 Proteins 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010023617 abarelix Proteins 0.000 description 1
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 1
- 229960002184 abarelix Drugs 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- RFQIWHDNNZFRBL-UHFFFAOYSA-N acetic acid;ethanol;hydrate Chemical compound O.CCO.CC(O)=O RFQIWHDNNZFRBL-UHFFFAOYSA-N 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000007040 multi-step synthesis reaction Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0104462A SE0104462D0 (sv) | 2001-12-29 | 2001-12-29 | Peptide purifcation (Peptidrening) |
| PCT/IB2002/005581 WO2003055900A1 (en) | 2001-12-29 | 2002-12-23 | Peptide purification |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005515217A JP2005515217A (ja) | 2005-05-26 |
| JP2005515217A5 true JP2005515217A5 (enExample) | 2005-12-22 |
| JP4378173B2 JP4378173B2 (ja) | 2009-12-02 |
Family
ID=20286556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003556430A Expired - Fee Related JP4378173B2 (ja) | 2001-12-29 | 2002-12-23 | ペプチド精製 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7057014B2 (enExample) |
| EP (1) | EP1468009B1 (enExample) |
| JP (1) | JP4378173B2 (enExample) |
| KR (1) | KR100880828B1 (enExample) |
| CN (1) | CN1272341C (enExample) |
| AT (1) | ATE449784T1 (enExample) |
| AU (1) | AU2002347550B2 (enExample) |
| CA (1) | CA2471717C (enExample) |
| DE (1) | DE60234535D1 (enExample) |
| DK (1) | DK1468009T3 (enExample) |
| ES (1) | ES2350880T3 (enExample) |
| IL (2) | IL162789A0 (enExample) |
| NO (1) | NO329024B1 (enExample) |
| NZ (1) | NZ534151A (enExample) |
| RU (1) | RU2303040C2 (enExample) |
| SE (1) | SE0104462D0 (enExample) |
| WO (1) | WO2003055900A1 (enExample) |
| ZA (1) | ZA200405135B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1359722A1 (en) * | 2002-03-27 | 2003-11-05 | BRITISH TELECOMMUNICATIONS public limited company | Data streaming system and method |
| EP1845973B1 (en) | 2005-01-21 | 2015-08-12 | Astex Therapeutics Limited | Pharmaceutical compounds |
| US8883790B2 (en) | 2006-10-12 | 2014-11-11 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US8916552B2 (en) | 2006-10-12 | 2014-12-23 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US9051349B2 (en) | 2007-11-21 | 2015-06-09 | Alba Therapeutics Corporation | Larazotide acetate compositions |
| EP2062909A1 (en) * | 2007-11-21 | 2009-05-27 | SOLVAY (Société Anonyme) | Peptide production and purification process |
| WO2009138488A1 (en) * | 2008-05-15 | 2009-11-19 | Novo Nordisk A/S | Purification of peptides prepared by solid phase synthesis |
| CN102482326A (zh) * | 2009-04-10 | 2012-05-30 | 科登制药科罗拉多公司 | 分离治疗用肽的方法 |
| CN107753954A (zh) | 2012-12-13 | 2018-03-06 | 免疫医疗公司 | 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量 |
| WO2015012904A2 (en) | 2012-12-13 | 2015-01-29 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
| US9931417B2 (en) | 2012-12-13 | 2018-04-03 | Immunomedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
| JP6427789B2 (ja) * | 2013-07-23 | 2018-11-28 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | Ｃｌ２ａリンカーを有する抗体−ｓｎ−３８免疫複合体 |
| RU2725292C2 (ru) | 2016-04-27 | 2020-06-30 | Иммьюномедикс, Инк. | Эффективность конъюгатов антитела против trop-2 с лекарственным средством sn-38 для терапии рецидивирующих/рефрактерных к ингибиторам контрольной точки опухолей |
| RU2758234C2 (ru) | 2017-03-27 | 2021-10-26 | Иммьюномедикс, Инк. | ЛЕЧЕНИЕ ТРИЖДЫ НЕГАТИВНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ, ХАРАКТЕРИЗУЮЩЕГОСЯ ЭКСПРЕССИЕЙ Trop-2, С ПОМОЩЬЮ САЦИТУЗУМАБА ГОВИТЕКАНА И ИНГИБИТОРА Rad51 |
| CA3044082A1 (en) | 2017-04-03 | 2018-10-11 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
| CN113952944B (zh) * | 2021-12-23 | 2022-03-29 | 浙江湃肽生物有限公司深圳分公司 | 一种纯化九肽-1的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8317697D0 (en) | 1983-06-29 | 1983-08-03 | Shell Int Research | Dissolution of peptides in non-aqueous and mixed non-aqueous/aqueous solvents |
| DE4001238A1 (de) * | 1990-01-18 | 1991-07-25 | Basf Ag | Verfahren zur anreicherung bzw. reinigung von biomolekuelen |
| DE19544212A1 (de) * | 1995-11-28 | 1997-06-05 | Asta Medica Ag | Neue LH-RH-Antagonisten mit verbesserter Wirkung |
| DE19813849A1 (de) * | 1998-03-27 | 1999-09-30 | Degussa | Verfahren zur einstufigen Umsalzung und Aufreinigung von Oligopeptiden |
| EP0998940A1 (en) | 1998-09-30 | 2000-05-10 | Laboratoire Theramex | Pharmaceutical compositions based on alpha-cyclodextrin for the oral administration of LH-RH analogues |
| DE19911771B4 (de) * | 1999-03-17 | 2006-03-30 | Zentaris Gmbh | LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung |
-
2001
- 2001-12-29 SE SE0104462A patent/SE0104462D0/xx unknown
-
2002
- 2002-12-23 AU AU2002347550A patent/AU2002347550B2/en not_active Ceased
- 2002-12-23 EP EP02783479A patent/EP1468009B1/en not_active Expired - Lifetime
- 2002-12-23 JP JP2003556430A patent/JP4378173B2/ja not_active Expired - Fee Related
- 2002-12-23 CN CNB028283481A patent/CN1272341C/zh not_active Expired - Fee Related
- 2002-12-23 AT AT02783479T patent/ATE449784T1/de not_active IP Right Cessation
- 2002-12-23 US US10/500,302 patent/US7057014B2/en not_active Expired - Fee Related
- 2002-12-23 DE DE60234535T patent/DE60234535D1/de not_active Expired - Lifetime
- 2002-12-23 KR KR1020047010363A patent/KR100880828B1/ko not_active Expired - Fee Related
- 2002-12-23 DK DK02783479.5T patent/DK1468009T3/da active
- 2002-12-23 ES ES02783479T patent/ES2350880T3/es not_active Expired - Lifetime
- 2002-12-23 RU RU2004119965/04A patent/RU2303040C2/ru not_active IP Right Cessation
- 2002-12-23 NZ NZ534151A patent/NZ534151A/en not_active IP Right Cessation
- 2002-12-23 CA CA2471717A patent/CA2471717C/en not_active Expired - Fee Related
- 2002-12-23 WO PCT/IB2002/005581 patent/WO2003055900A1/en not_active Ceased
- 2002-12-23 IL IL16278902A patent/IL162789A0/xx unknown
-
2004
- 2004-06-28 ZA ZA2004/05135A patent/ZA200405135B/en unknown
- 2004-06-29 IL IL162789A patent/IL162789A/en not_active IP Right Cessation
- 2004-07-16 NO NO20043046A patent/NO329024B1/no not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4378173B2 (ja) | ペプチド精製 | |
| JP5850458B2 (ja) | デガレリックスの製造方法 | |
| CA1315229C (en) | Chromatographic purification process | |
| CH627151A5 (enExample) | ||
| EP0401109A1 (fr) | Microprotéines, procédé de préparation et application à titre de médicaments de ces microprotéines | |
| CN100584859C (zh) | 制备棘白菌素衍生物的方法 | |
| JP2980689B2 (ja) | シクロスポリンａの製造方法 | |
| SU1396970A3 (ru) | Способ получени производных гонадолиберина | |
| EP0955308A1 (de) | Verfahren zur einstufigen Umsalzung und Aufreinigung von Oligopeptiden | |
| JPH0570495A (ja) | 環式ヘキサペプチド化合物 | |
| AU613640B2 (en) | Chromatographic purification process | |
| US4512923A (en) | Luteinizing and follicle stimulating hormones and process for the preparation thereof | |
| WO2016012938A2 (en) | Improved process for preparation of amorphous linaclotide | |
| EP1189932A1 (fr) | Derives de l'echinocandine, leur procede de preparation et leur application comme antifongiques | |
| EP1189933B1 (fr) | Derives de l'echinocandine, leur procede de preparation et leur application comme antifongiques | |
| HK1076112B (en) | Peptide purification | |
| CN1763084B (zh) | 高纯度环孢菌素a的制备方法 | |
| MX2008006361A (en) | Purification processes of echinocandin-type compounds | |
| JPH08502299A (ja) | シクロヘキサペプチジルアミンのアミノ酸複合体 | |
| PL179597B1 (pl) | Sposób otrzymywania wysokiej czystości octanów peptydów-analogów LHRH | |
| DD285097A5 (de) | Verfahren zur herstellung des undecapeptides substanz p |